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The concept that a persistent viral infection can be
associated with untoward consequences temporally re-
mote from the initial infection is now a familiar one.
Examples include the immunodeficiency caused by HIV,
spastic paraparesis associated with HTLV-1, chronic
hepatitis and the attendant progressive cirrhoses asso-
ciated with HBV and HCV, and the neurological diseases
SSPE, and PML associated with persistence of measles
and polyomavirus, respectively. The agents which cause
these diseases are all of exogenous origin and the re-
spective tissue pathologies are either a consequence of
direct cytopathic effects of the virus infection or second-
ary to inflammatory responses it engenders. Generally
signs of persistent viral gene expression can be de-
tected throughout the course of disease.
There is abundant evidence from animal models that
viruses can also cause chronic diseases by inducing
autoimmunity (Oldstone and von Herrath, 1996). Viral
antigens can structurally “mimic” self-antigens and initi-
ate an immune response which cross-reacts with the
respective autoantigens (molecular mimicry) (Fujinami
and Oldstone, 1985). This then sets the stage for a local
inflammatory response near the site of autoantigen ex-
pression, which in turn leads to tissue damage. Viruses
need not necessarily persist. Once started, the autore-
active process can be self-sustaining through “epitope
spreading” (Miller et al., 2001). Much of what we know
about these mechanisms has come primarily from stud-
ies in animal models, but there is compelling epidemio-
logic evidence that virus infection in humans predis-
poses one to autoimmune diseases. The reader is re-
ferred to a recent review on the subject (von Herrath,
2000).
It has become apparent that essentially all eukaryotes
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retroviral genomes archived within their genomic DNA.
The potential capacity of these elements to move about
the genome, modifying host genes or their expression
programs, and the ability of some retroviral proteins to
modulate immune responses, has suggested that these
prototypical “persistent viruses” might also have a hand
in autoimmune diseases (Lo¨wer, 1999;Nakagawa and
Harrison, 1996). Following is a discussion of the nature of
the evidence and the placement of some of these obser-
vations in a historical perspective drawn from animal
studies.
HERV basics. Nearly 50% of the human genome con-
sists of retroelements which include long interspersed
elements (LINEs), short interspersed elements (SINEs),
and retrovirus-like elements which include the human
endogenous retroviruses (HERVs). The latter group
makes up at latest count approximately 8% of the human
genome (ca 450,000 copies) (International Human Ge-
nome Sequencing Consortium, 2001). HERVs are di-
vided, based on relatedness in phylogenic trees, into
three classes and are named based on the sequence of
their respective tRNA primer-binding sites (Tristem,
2000). Thus, HERV-W is predicted to use tRNAtrp, HERV-K,
tRNAlys, and so forth. These elements are all remnants of
ancient infections by exogenous retroviruses which, with
rare exceptions (Medstrand and Mager, 1998), occurred
prior to divergence of hominid from Old World mon-
keys  25 million years ago. Because of accumulated
mutations and deletions, these elements are considered
to be replication defective (International Human Genome
Sequencing Consortium, 2001), although recent studies
suggest that some members of the HERV-K group appear
structurally to have the capacity for producing infectious
virus (Turner et al., 2001). Nevertheless, no infectious
HERV has yet been identified. The apparent absence of
replication-competent endogenous retroviruses in hu-
mans is in striking contrast to mice, pigs, and birds, inReceived January 25, 20
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which infectious endogenous viruses can be consis-0042-6822/02
tently detected and in which new somatic and germ line
proviral integrations continue to occur.
Is the mouse a good model for retrovirus-induced
autoimmunity? One of the most studied animal models of
autoimmune disease is the systemic lupus-like condition
exhibited by certain strains of mice (Bielschowsky and
D’Ath, 1971). Many of the mouse strains that develop this
disease also express high levels of replication-compe-
tent endogenous viruses and have high serum levels of
endogenous retroviral envelope protein. The mice also
produce antiviral antibodies, have circulating immune
complexes containing viral proteins, and exhibit deposi-
tion of these immune complexes in the kidneys (Yoshiki
et al., 1974). Yet, genetic studies have shown that expres-
sion of endogenous viruses and viral protein segregates
independently of disease (Datta et al., 1978a,b). This
means that disease can progress even in the absence of
viral gene expression, implying that the primary abnor-
malities in these mice are immunological not virological
in nature. The viral proteins in this case can act as
autoantigens and contribute to the disease (Tucker et al.,
2000), but other autoantigens likely play a more impor-
tant role. Certainly there is no evidence that endogenous
retroviruses or their products have any role to play as
initiators or “triggers” of autoimmune disease in mice.
Evidence supporting a role for HERVs in autoimmune
diseases. A discussion of a potential role of HERVs in
human autoimmune diseases has generally focused on
multiple sclerosis (MS), Sjo¨gren’s syndrome (SS), sys-
temic lupus erythematosis (SLE), insulin-dependent dia-
betes mellitus (IDDM), a form of heart disease called
congenital heart block (CHB), and primary biliary cirrho-
sis (PBC). With the exception perhaps of CHB, none of
these diseases consists of a clear-cut clinical entity.
Each is subdivided into a number of subtypes based on
clinical presentation, qualitative features of the pathol-
ogy, and age of onset. The heterogeneous nature of
these disorders alone makes the task of identifying any
specific risk factor a daunting one. Nevertheless, let us
consider the nature of the evidence for involvement of
HERVs in these diseases.
Antiviral immune response. Circulating antibodies re-
active with endogenous retroviral proteins have been
reported in patients suffering from all of the diseases
mentioned above. For example, antibodies reactive with
peptides present in the envelope genes of HERV-H are
found in SLE patients (Bengtsson et al., 1996) and anti-
bodies reactive with HERV-W peptides have been found
both in sera and CSF of MS patients (Jolivet-Reynaud et
al., 1999). Antibodies to a HTLV-Related Endogenous
Sequence (HRES), a single copy HERV, are detected in
patients with SLE (Perl et al., 1995). Antibodies to ERV-3
(a member of the HERV-R family) are seen in patients
with SLE and SS, and transplacental transfer of maternal
anti-ERV-3 antibodies appears to correlate with the oc-
currence of myocarditis and cardiac arrhythmia (CHB) in
the developing fetus (Li et al., 1996). Antibodies reactive
with intracysternal A particles (IAP) have been detected
in patients with IDDM, SS, and SLE (Mason et al., 1999).
Significantly, patients with SS, PBC, and SLE have circu-
lating antibodies reactive with HIV p24, but in the ab-
sence of antibodies to HIV env (Mason et al., 1999). Thus,
these patients were not HIV infected, suggesting the
possibility that these represent cross-reactive antibodies
to another retrovirus. However, anti-HIV p24 antibodies
detected in SS and SLE patients have been found to
cross-react with a host ribonucleoprotein autoantigen
(Sm) (Talal et al., 1992). The epitope to which these
antibodies react is a proline-rich region shared by a wide
variety of proteins, and binding was fully inhibited by
polyproline peptides. What antigen is actually driving this
antibody response is unclear. More recent studies using
combinatorial peptide libraries have revealed surprising
levels of cross-reactivity of both antibodies (Marchalonis
et al., 2001) and T cell receptors (Wucherpfennig, 2001),
often not predicted by database searches for sequence
homology. Thus, particularly in the context of the immune
dysregulation associated with autoimmune disease, the
existence of serum antibodies or T cells reactive with
particular endogenous retroviral proteins or peptides
does not necessarily indicate that those antigens were
driving the immune response and would not necessarily
imply that the cognate viral protein was actually ex-
pressed. Certainly the existence of autoreactive antibod-
ies or T cells would be of little consequence without
expression of the target antigen. In this regard it is worth
considering that with rare exceptions (Li et al., 1996),
little is known about the expression of HERV proteins at
the tissue or cellular level.
Viral gene expression. Endogenous retroviral gene ex-
pression has been detected in the diseases IDDM, MS,
SS, SLE, and PBC. Transcripts of gag, pol, and in some
cases env are detectable by RT-PCR and in MS (Perron et
al., 1997) and IDDM (Conrad et al., 1997), extracellular
virus-like particles have been found apparently contain-
ing RNA resembling HERV-W and HERV-K classes, re-
spectively. It should be noted that extracellular particle
formation requires only the expression of retroviral core
proteins and does not indicate the presence of infectious
virus. Nevertheless, the epidemiology of viral gene ex-
pression appears to indicate a good correlation with the
respective diseases, and the possibility that retroviral
gene expression is involved in the pathogenesis of these
diseases cannot be dismissed. It is worth noting, how-
ever, that the promoters of endogenous retroviral genes,
similar to those of exogenous retroviruses, contain bind-
ing sites for a variety of transcription factors also in-
volved in the transcription of genes involved in inflam-
matory responses. Thus, HERV expression could be a
response to, rather that the cause of, these diseases.
That HERV expression can indeed be upregulated by
products of the inflammatory responses is illustrated by
2 MINIREVIEW
in vitro studies showing that TNF, IL-1, and IL-1
increased transcription of HERV-R sequences in human
vascular endothelial cells (Katsumata et al., 1999). In a
recent study (Johnston et al., 2001) expression of a vari-
ety of HERV mRNAs was observed to increase on expo-
sure of macrophages in vitro to PMA and this was also
associated with the release of extracellular virus-like
particles. More to the point, however, RT-PCR was used
to assess expression of a variety of HERV mRNAs in
brain tissue from cases of HIV encephalitis, MS, and
Alzheimer’s disease. Each of these diseases involves
some level of chronic inflammation. mRNA levels of
HERV-W, K, and H were found to be increased in brain
(two- to fourfold) in these cases. It is difficult, therefore, to
interpret the significance of HERV expression at either
the RNA or the protein level in the face of a local chronic
inflammatory response. Certainly if HERV gene expres-
sion participates in these diseases, it is likely to have a
supportive rather than a initiating role.
HERV’s as superantigens. Expansion of autoreactive T
lymphocytes could be induced by a superantigen (SAG)
which activates T cells bearing specific V chains irre-
spective of the peptide specificity of the T cell receptor
(Marrack et al., 1993). Such T cell activation might also
intensify a local inflammatory response by virtue of the
secretion of cytokines and chemokines (i.e., “bystander”
effect) and, in the presence of the cognate autoantigen,
evolve into an antigen driven process. Indeed it has been
shown that staphylococcal enterotoxin B (a potent bac-
terial superantigen) can increase the severity of experi-
mental autoimmune encephalitis in mice, one animal
model of MS (Brocke et al., 1993). Both endogenous and
exogenous Type B retroviruses of mice (mouse mam-
mary tumor virus) express a superantigen call SAG
(Ross, 2000) which functions to either expand or delete
specific T cell subsets. The SAG of exogenous MMTV is
involved in the expansion of the initial target cell pool
required for transit of virus from the gut to the mammary
glands. The expression of SAG by endogenous copies of
MMTV, which occurs during early T cell development,
results in deletion of T cell populations and appears to
actually protect the mouse from infection by exogenous
MMTV by preventing the initial SAG-driven T cell stimu-
lation.
There is some evidence for skewing of T cell popula-
tions in favor of those bearing specific V chains in two
childhood diseases, a form of heart disease called idio-
pathic dilated cardiomyopathy (V3, 7, and 13) (Luppi et
al., 2001) and in IDDM (V7 and 13) (Conrad et al.,
1994;Luppi et al., 2000). These observations have sug-
gested the possibility that a superantigen may be ex-
pressed in the respective target organs in these dis-
eases. It was therefore of great interest when an
endogenous envelope sequence related to HERV-K
(IDDMK1,222), apparently encoding a protein with proper-
ties of a V7-specific superantigen, was identified in
pancreatic islets of patients with IDDM (Conrad et al.,
1997). These studies have been subjected to reexamina-
tion by a number of other laboratories looking at different
IDDM cohorts. Neither the disease-specific nature of this
endogenous virus (Murphy et al., 1998;Lan et al., 1998;
Jaeckel et al., 1999) nor expression of HERV-K encoded
superantigenic activity (Lapatschek et al., 2000) was con-
firmed. However, a major problem in assessing the im-
portance of any specific HERV in disease pathogenesis
is the large number of copies of each HERV family
scattered throughout the genome. There appear to be
30–50 copies of HERV-K pol sequences in the human
genome. Thus, it was not clear that each of these studies
was actually examining the same HERV mRNA.
Some of the confusion on this issue has been resolved
with the recent genetic mapping of a polymorphic provi-
ral sequence, HERV-K18 with 99% sequence homology to
the env sequence of IDDMK1,222 (Hasuike et al., 1999). It
is located in the first intron of the CD48 gene on chro-
mosome 1. This is a solitary retroviral envelope gene with
three alleles differing in sequence and coding capacity
(Stauffer et al., 2001). Interestingly, transcription of this
env gene is upregulated by IFN and all three alleles of
this gene encode superantigenic activity associated with
rapid expansion of V7 T cells (Stauffer et al., 2001). In
another study, HERV-K18 was shown to also expand
V13 T cells (Sutkowski et al., 2001), another subpopu-
lation which may be associated with IDDM (Luppi et al.,
2000). Finally, there is some anecdotal evidence that
other, as yet, unidentified HERV-encoded SAGs may exist
(Sutkowski et al., 2001) and a recent report suggests that
an env protein of the MS-associated HERV-W (MSRV)
may also have properties of a SAG (Perron et al., 2001).
Concluding remarks. The studies on HERV-K18
present the first clear evidence that human endogenous
retroviruses can encode superantigenic activity. Further-
more, the finding that expression of HERV-K18 is regu-
lated by IFN suggests that infection by an exogenous
virus might initiate the expansion of autoreactive T cells
in an organ-specific fashion, based on the tissue tropism
of the exogenous virus. This is particularly interesting in
the context of IDDM in which a rather strong association
with enterovirus infection of the pancreas and increased
local production of IFN has been observed (Chehadeh
et al., 2000). Also worth noting is the finding of human
herpes virus-6 gene expression at both the mRNA and
the protein level within brain lesions in multiple sclerosis
(Challoner et al., 1995). Recent studies indicate that the
herpesvirus EBV induces expression of the HERV-K18-
encoded SAG (Sutkowski et al., 2001). Interestingly, this
effect is indirect, operating through an EBV-inducible
transcriptional enhancer of the CD48 gene, the gene in
which the HERV-K18 env gene is embedded. This then
provides a second possible means by which an exoge-
nous virus infection could activate expression of an en-
dogenously encoded SAG. A third mechanism for endog-
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enous SAG expression is the HERV activation associated
with ongoing inflammatory responses (Johnston et al.,
2001), described above.
The idea that an endogenous SAG might be expressed
in response to an infection exogenously acquired pro-
vides another model, in addition to molecular mimicry,
which could explain the link between virus infection and
autoimmune diseases. Certainly, many questions re-
main. How many HERV-encoded SAGs exist? What is the
developmental program of SAG expression and why are
the SAG-reactive T cells not deleted? Do these SAGs
actually participate in autoimmune diseases and/or do
they perhaps play a role in normal immune or inflamma-
tory responses? The involvement of endogenous SAGs
as contributors to disease pathogenesis has not, to my
knowledge, been described in any animal systems.
Since endogenous MMTV sequences encode well-char-
acterized SAGs in mice, this might be an appropriate
model to investigate such a connection.
Although endogenous retroviral sequences have re-
sided in the human genome for a very long time and are
thought to be sessile elements, there is emerging evi-
dence that HERV polymorphisms exist (Stoye, 2001).
Clearly, as more individual human genomes are sub-
jected to analysis, more will be learned about allelic
variation among HERV sequences and the existence of
linkages to human disease. Additionally, the possible
induction of endogenous SAG by exogenous viruses
provides a tantalizing conceptual model. As it stands,
however, the role of HERVs in autoimmune diseases
remains elusive.
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